Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment

Inclusion Criteria * Females aged 18 to 45 years * Subjects presenting with Heavy Menstrual Bleeding (HMB) * Subjects with Pictorial Blood Assessment Chart (PBAC) score of 100 or more * Subjects will be treated with dydrogesterone in accordance to the local label after enrollment in the trial Exclusion Criteria * Subjects with structural or organic pathology as an underlying cause of HMB. * Subjects with hypersensitivity to dydrogesterone * Known or suspected progestogen dependent neoplasms * Subjects with vaginal bleeding who have not been screened for organic or structural pathology as an underlying cause * Subjects with acute or chronic liver disease * Patients with depressive illness * Subjects who are known to have rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption * Nursing mothers * Use of any other medication for uterine bleeding (including but not limited to progesterone, oral contraceptive pills, tranexamic acid etc) * Use of Non-Steroidal Anti inflammatory Drugs (NSAIDs)